19 May London (UK) and Tokyo (Japan) MRC Technology and Keio University School of Medicine have signed a memorandum of understanding outlining their collaboration to identify promising antibody and small molecule research and translate them into early stage assets. By combining capabilities, the partnership aims to accelerate discovery to a stage where it is ready for clinical development by pharmaceutical companies and ultimately benefit patients.

MRC Technology, a medical research charity, aims to find treatments in areas of unmet patient needs. It offers commercialisation and intellectual property (IP) management skills and diagnostic and drug discovery expertise, specialising in small molecules and therapeutic antibodies.

Keio University is a modern institution found on ‘jitsugaku’ (science) based learning. It has developed expertise in a wide range of therapeutic areas, including cancer, cardiovascular and metabolic diseases.

MRC Technology has a similar agreement in place with Tokyo University.